The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtype
Crossref DOI link: https://doi.org/10.1186/s12885-015-1819-3
Published Online: 2015-10-24
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Need, Eleanor F.
Selth, Luke A.
Trotta, Andrew P.
Leach, Damien A.
Giorgio, Lauren
O’Loughlin, Melissa A.
Smith, Eric
Gill, Peter G.
Ingman, Wendy V.
Graham, J. Dinny
Buchanan, Grant
License valid from 2015-10-24